Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Horlings

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
BMC Cancer|April 10, 2019
A specific gene expression signature for visceral organ metastasis in breast cancerC D Savci-Heijink, H Halfwerk, J Koster, et al.
The Netherlands Journal of Medicine|December 1, 2010
Left-sided native valve Staphylococcus aureus endocarditisM Slabbekoorn, H M Horlings, J T M van der Meer, et al.
Breast Cancer Research and Treatment|January 6, 2019
Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behaviorC D Savci-Heijink, H Halfwerk, G K J Hooijer, et al.
NPJ Breast Cancer|April 28, 2022
Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancerI Nederlof, S Hajizadeh, F Sobhani, et al.
The Journal of Pathology|August 23, 2008
Refinement of breast cancer classification by molecular characterization of histological special typesB Weigelt, H M Horlings, B Kreike, et al.
Blood Cancer Journal|September 10, 2013
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesW Kraan, H M Horlings, M van Keimpema, et al.
Leukemia|November 21, 2013
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphomaW Kraan, M van Keimpema, H M Horlings, et al.
Oncogene|January 27, 2010
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsN Turner, M B Lambros, H M Horlings, et al.
NPJ Breast Cancer|April 18, 2024
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockadeM C Liefaard, A van der Voort, M van Seijen, et al.
Breast (Edinburgh, Scotland)|July 2, 2023
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trialV C M Geurts, L Voorwerk, S Balduzzi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Cancer|April 10, 2019
A specific gene expression signature for visceral organ metastasis in breast cancerC D Savci-Heijink, H Halfwerk, J Koster, et al.
The Netherlands Journal of Medicine|December 1, 2010
Left-sided native valve Staphylococcus aureus endocarditisM Slabbekoorn, H M Horlings, J T M van der Meer, et al.
Breast Cancer Research and Treatment|January 6, 2019
Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behaviorC D Savci-Heijink, H Halfwerk, G K J Hooijer, et al.
NPJ Breast Cancer|April 28, 2022
Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancerI Nederlof, S Hajizadeh, F Sobhani, et al.
The Journal of Pathology|August 23, 2008
Refinement of breast cancer classification by molecular characterization of histological special typesB Weigelt, H M Horlings, B Kreike, et al.
Blood Cancer Journal|September 10, 2013
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesW Kraan, H M Horlings, M van Keimpema, et al.
Leukemia|November 21, 2013
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphomaW Kraan, M van Keimpema, H M Horlings, et al.
Oncogene|January 27, 2010
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsN Turner, M B Lambros, H M Horlings, et al.
NPJ Breast Cancer|April 18, 2024
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockadeM C Liefaard, A van der Voort, M van Seijen, et al.
Breast (Edinburgh, Scotland)|July 2, 2023
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trialV C M Geurts, L Voorwerk, S Balduzzi, et al.
Pageof 2